Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

November 10, 2020 8:00 AM

BOSTON, MA / ACCESSWIRE / November 10, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences: Jefferies Virtual London Healthcare...

Read more

American Screening Corporation Enables Speedy and Efficient Decision-Making with Vast Selection of Rapid Drug Tests

November 9, 2020 7:00 PM

SHREVEPORT, LA / ACCESSWIRE / November 9, 2020 / Despite the social progress and economic prosperity achieved in the past few decades, certain issues remain a common challenge for nations worldwide. One of them is illicit drug use, which has been straining healthcare budgets, affecting workplace productivity, and endangering public safety. However, medical and technological advances have enabled government agencies, healthcare...

Read more

Helix BioPharma Corp. Signs Definitive Agreement to Fully Divest Polish Subsidiary

November 9, 2020 5:00 PM

RICHMOND HILL, ON / ACCESSWIRE / November 9, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has signed a definitive share purchase agreement with CAIAC Fund Management AG ("CAIAC"), as designed trustee of HIO Fund...

Read more

Applied UV, Inc. Announces Non-Binding Letter of Intent to Acquire the Airocide(TM) System for Airborne Pathogen Reduction

November 9, 2020 3:15 PM

MOUNT VERNON, NY / ACCESSWIRE / November 9, 2020 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection prevention technology company that applies the power of ultra violet C ("UV-C") light utilizing its patented devices to destroy pathogens, including bacteria and viruses, safely, thoroughly, and automatically, today announced that in addition to its exclusive Joint Distribution and...

Read more

American Screening Corporation Offers Comprehensive Choice of Urine and Saliva Drug Tests

November 8, 2020 11:35 PM

SHREVEPORT, LA / ACCESSWIRE / November 8, 2020 / For close to 17 years, American Screening Corporation (ASC) has been supporting efforts to combat substance abuse and addiction by providing a vast array of drug testing products and striving to offer the best possible prices without compromising on quality. This has helped the Shreveport, Louisiana-based company become an ISO13485 contract manufacturer and one of the leading distributors of...

Read more

Edesa Biotech to Present at H.C. Wainwright & Co. 6th Annual Israel Conference

November 6, 2020 8:00 AM

TORONTO, ON / ACCESSWIRE / November 6, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to present at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020 at 12:30 pm ET. Edesa senior management will be available during the conference for one-on-one meetings. Members of the investment community who are interested...

Read more

Visioneering Technologies, Inc. to Present at the SNN Network Australia Virtual Event on Wednesday 11 November 2020 8:30 am Sydney Time (Tuesday 10 November at 4:30 pm New York Time)

November 5, 2020 7:40 PM

ATLANTA, GA / ACCESSWIRE / November 5, 2020 / Visioneering Technologies (ASX:VTI), US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses Visioneering Technologies, Inc. is pleased to announce that it will be participating in the SNN Network Australia Virtual Event. The company presentation will be held on Wednesday 11 November 2020 at 8:30 am Sydney Time. Chief Executive...

Read more

Apollo Endosurgery, Inc. Reports Third Quarter 2020 Results

November 5, 2020 4:01 PM

Global Endoscopy Product Sales Increase 21% Year-Over-Year Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET AUSTIN, TX / ACCESSWIRE / November 5, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the third quarter ended September 30, 2020. Third Quarter 2020 and...

Read more

Hancock Jaffe Announces Date for VenoValve Pre-IDE Meeting with FDA

November 5, 2020 1:45 PM

Meeting with FDA Set for December 22 IRVINE, CA / ACCESSWIRE / November 5, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Pre-IDE meeting with the U.S. Food and Drug Administration ("FDA") regarding the VenoValve U.S. pivotal trial has been set for December 22, 2020. Topics to be discussed at the December 22 virtual meeting...

Read more

Applied UV, Inc. Subsidiary, SteriLumen, Inc., Announces Receipt of Additional Purchase Order for Airocide(TM) System From Hyatt Hotel's Dubai Creek Golf & Yacht Club Resort

November 5, 2020 8:13 AM

MOUNT VERNON, NY / ACCESSWIRE / November 5, 2020 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection prevention technology company that applies the power of narrow-range ultraviolet light ("UVC") utilizing its patented devices to destroy pathogens, including bacteria and viruses safely, thoroughly, and automatically, today announced that its subsidiary, SteriLumen, Inc....

Read more

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 6th Annual Israel Conference

November 5, 2020 8:05 AM

- Live video webcast with CEO, Jeffrey Eisenberg, on Tuesday, November 12th at 8:00 AM EST - FRAMINGHAM, MA / ACCESSWIRE / November 5, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey...

Read more

Lexaria Bioscience Advances 2021 Strategic Initiatives

November 5, 2020 6:45 AM

Lexaria Focusing on Four Core Business Segments: Heart disease including hypertension Reduced-risk non combusted nicotine Improved antiviral drug delivery CBD from hemp KELOWNA, BC / ACCESSWIRE / November 5, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in oral drug delivery platforms, is pleased to outline its planned strategic initiatives for 2021...

Read more

Applied UV, Inc. Announces Non-Binding Letter of Intent to Acquire the Airocide(TM) System for Airborne Pathogen Reduction

November 4, 2020 8:30 AM

MOUNT VERNON, NY / ACCESSWIRE / November 4, 2020 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection prevention technology company that applies the power of ultra violet C ("UV-C") light utilizing its patented devices to destroy pathogens, including bacteria and viruses, safely, thoroughly, and automatically, today announced that in addition to its exclusive Joint Distribution and...

Read more

Pieris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 4, 2020 7:00 AM

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, NOVEMBER 4, 2020 AT 8:00 AM EST PRS-060/AZD1402 first regulatory submission for global phase 2a study has been made; site initiation and patient screening expected this year PRS-343 in-use studies requested by FDA are completed; forthcoming meeting with FDA to align on path for continued development PRS-343 phase 1 monotherapy and atezolizumab combination data at ESMO...

Read more

Tetra Bio-Pharma Provides Update on Market Potential of ARDS-003

November 4, 2020 6:30 AM

Initial Drug Indication Targets COVID-19 Related Survival Benefits Cost-Saving Including When Used With a Remdesivir™ Standard of Care Expanded Post-Survival Indications (Reduce the Risk of Fibrosis and Multi-Organ Dysfunctions) Tetra Estimates Potential Revenues From Royalties on Net Sales, Milestone and Upfront Payments of Over $500 Million USD by 2026 OTTAWA, ON / ACCESSWIRE / November 4, 2020 / Tetra Bio-Pharma Inc....

Read more

Apollo Endosurgery to Present at November Investor Conferences

November 3, 2020 8:00 AM

AUSTIN, TX / ACCESSWIRE / November 3, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that its management team will participate in two upcoming investor conference events during November 2020. November 17, 2020 Craig Hallum Alpha Select Investor Conference Apollo will participate in one on one meetings...

Read more

Edesa Biotech Achieves Enrollment Milestone in Dermatitis Study

November 3, 2020 7:25 AM

TORONTO, ON / ACCESSWIRE / November 3, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment of more than 50% of the patients planned for the first cohort of a Phase 2b clinical study evaluating the company's drug candidate as a monotherapy for chronic allergic contact dermatitis. The adaptive, double-blind study is evaluating the safety and efficacy of EB01...

Read more

Wuhan General Group Announces Medspresso & Handcrafted Delights Launch Event in Cape Town

November 2, 2020 9:30 AM

CAPE TOWN, SA / ACCESSWIRE / November 2, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following update on its Medspresso and Handcrafted Delights brands: The Launch Announcement The launch of Medspresso and Handcrafted Delights will be celebrated November 7th, 2020...

Read more

Mymetics Starts Second Preclinical Study for Virosome-based Covid-19 Vaccine

November 2, 2020 8:00 AM

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform, evaluating different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine. Under the TRANSVAC2 program, funded by the European Commission through the Horizon 2020 framework, Mymetics has started a preclinical study at the Helmholtz Center of Infection Research in...

Read more

Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of Quatramer(TM) Technology with HDAC6-PI3Kδ Dual Inhibitor for AML

November 2, 2020 8:00 AM

BRIDGEWATER, NJ / ACCESSWIRE / November 2, 2020 / Hillstream BioPharma, Inc. ("Hillstream", the "Company") today announced the second renewal of a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH). The agreement enables NCATS's use of the company's Quatramer™ drug delivery technology. This...

Read more